FluGen flu vaccine research ramps up as work on COVID-19 candidate slows
FluGen Announces Publication of Positive Results from Phase 2 Human Challenge Study of Its M2SR Vaccine Candidate Against Highly Drifted Strain of H3N2 Influenza Virus
FluGen Awarded US Department of Defense Funding to Conduct Clinical Study Evaluating Investigational M2SR Flu Vaccine and Current Standard-of-Care High Dose Vaccine
